320 results about "Zeaxanthin" patented technology

A nutritional supplement composition that promotes visual health and reduces or reverses visual acuity loss by a reduced Vitamin E content from standard supplements with the addition of taurine, omega-3 fatty acids, and non proform Vitamin A carotenoids including lutein and zeaxanthin. The essential ingredients of the nutritional or dietary supplements are Vitamin C, no more than 300 IUs of Vitamin E, Vitamin A at least a portion of which is provided in the form of a proform Vitamin A carotenoid, omega-3 fatty acids, and non proform Vitamin A carotenoids including lutein and/or zeaxanthin. The essential ingredients are provided in a form suitable of oral ingestion or other forms of administration in one or more doses per day.

Dairy or non-diary based fortified carbonated beverage solutions that supply essential nutrients in the human diet. The solution contains per 354 ml, calcium, magnesium and potassium ions in the form of salts and optionally vitamins A, D, C, lutein, zeaxanthin and folic acid in specified amounts to provide dietary supplementation. Sweeteners, stabilizers, flavors and carbonation can also be added to enhance flavor, taste, mouth-feel, ingredient solubilization and product appearance. A method of making the beverages is also described. A method of using carbonation to reduce bacterial counts and reduce degradation of essential nutrients in milk-based beverages with or without pasteurization is also disclosed.

The present invention describes an improved commercial process for the production of carotenoid-cyclodextrin complexes and formulation of the complex for human ingestion. Complexation with cyclodextrins (e.g., α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, or HP-β-cyclodextrin) significantly improves the uptake of carotenoids (e.g., lycopene, lutein, or zeaxanthin) and their mixtures in vitro. The method for making such complexes includes forming a carotenoid/cyclodextrin complex; freezing drying said carotenoid/cyclodextrin complex; and blending said freeze-dried carotenoid/cyclodextrin complex with a mixture of lecithin and a vegetable oil or a vegetable oil suitable for soft gelatin capsules. The cyclodextrin/carotenoid complex can be formed in a molar ratio of between about 0.5:1.0 and 10:1. In vivo, in a human study, the lutein/γ-cyclodextrin complex formulated in lecithin-oil or oil showed a better absorption of lutein, as compared to the free lutein-oil formulation.

Administering water-soluble or dispersible synthetic analogs or derivatives of astaxanthin, lutein, zeaxanthin, or lycophyll and/or other carotenoids to a subject may reduce some of the adverse effects of inflammation in a body organ or tissue. The analogs or derivatives may be incorporated into pharmaceutical, over-the-counter, or nutraceutical preparations. Administration of the analogs or derivatives described herein may reduce deposition of inflammatory mediators such as C-reactive protein, complement system proteins or the membrane attack complex (MAC) in tissues. Reduced deposition of these molecules in tissues may reduce cell damage and/or lysis in the tissues.

A method used for synthesizing intermediates for use in the synthesis of carotenoids and carotenoid analogs, and/or carotenoid derivatives. In some embodiments, the invention includes methods for synthesizing optically active intermediates useful for the synthesis of optically active carotenoids. Synthesis of optically active carotenoids, in one embodiment, may be accomplished by forming an optically active dihydroxy intermediate from ketoisopherone. The optically active dihydroxy intermediate may be converted into optically active zeaxanthin.

The present invention provides improved dietary supplements and methods for inhibiting the progression of macular degeneration and promoting healthy vision, while at the same time maintaining general health. The dietary supplements of the invention contain vitamin E and carotenoids in the form of Vitamin A, lutein and/or zeaxanthine. The dietary supplements of the invention further contain Vitamin C, copper and zinc and may also contain such ingredients as rosemary, DHA, and other vitamins and minerals.

The invention relates to a health food with a function of relieving visual fatigue and a preparation method thereof, belonging to the technical field of health foods. The health food with the function of relieving visual fatigue is characterized in that active ingredients and additives are used for preparing the health food into soft capsules, hard capsules, oral liquid or tablets, wherein the active ingredients comprise the following raw materials: flaxseed oil or perilla oil, beta-carotene or vitamin A, lutein, zeaxanthin, vitamin E, ginkgo leaf extract and grape pip extract or cowberry extract; when the health food is prepared into the soft capsules, an emulsifying agent is used as the additive; when the health food is prepared into the hard capsules, a diluting agent is used as the additive; when the health food is prepared into oral liquid, a preservative, a flavoring agent, an emulsifying agent and water are used as the additives; and when the health food is prepared into the tablets, a diluting agent and a disintegrating agent are used as the additives. The health food prepared by the invention has the function of relieving visual fatigue.

The invention discloses a beta-carotene micro-capsule and the preparation method thereof. The beta-carotene comprises one of lycopene, lutein, zeaxanthin and astaxanthin or the mixture thereof, belonging to the fields of drugs and health care products. The beta-carotene micro-capsule is composed of the following raw materials by weight proportions: beta-carotene: lipid material: capsule material: emulsifier: water equals to 1:1-20:1-20-1-10:80-100. The invention adopts a two-phase emulsion spray drying method to prepare the beta-carotene micro-capsule, which has good light and thermal stability and water-solubility or water dispersivity.

Zeaxanthin (ZX) or other medically or commercially important carotenoids can be prepared in microcrystalline form, in an oily carrier liquid, to increase their bioavailability following oral ingestion. Initial processing is carried out to prepare a “rough” or “coarse-grained” carotenoid preparation containing relatively large particles of the ZX or other carotenoid, in a suitable form such as a lyophilized stable powder. The coarse-grain preparation is dissolved in a suitable solvent such as tetrahydrofuran, and mixed with a carrier liquid comprising a digestible oil (such as a vegetable oil) and an emulsifying agent. The resulting oil-and-solvent mixture is injected, along with inert gas such as nitrogen, into a vacuum chamber, where a suitable vacuum and temperature combination is used to remove the solvent in a rapid “flash” manner which does not give the carotenoid crystals time to grow larger through accretion or aggregation. This generates a microcrystalline suspension containing very small particles of the ZX or other cartenoid, in the oily liquid carrier. This product can be further processed if desired, or it can be loaded directly into watertight capsules for oral ingestion. Tests on human volunteers have confirmed that the bioavailability of this microcrystalline form is substantially higher than prior art preparations having larger particles of the carotenoid.

Embodiments include a composition to promote ocular health and a method of treatment for a subject exposed to a source of oxidative or visual stress to the eye or having a degradation of the eye. The composition may include amounts of vitamin A, which includes beta-carotene; vitamin C; vitamin D; vitamin E; zinc; copper; selenium; non-vitamin A carotenoids, which include lutein and zeaxanthin; omega-3 fatty acids, which include eicosapentaenoic acid and docosahexaenoic acid; taurine; alpha lipoic acid; pine bark extract; astaxanthin; and Piper spp. extract. The method includes the step of administering to the subject a daily dose of a composition to promote ocular health.

Zeaxanthin, a natural carotenoid, can improve and increase the ability of enzyme inhibitors that can slow down certain enzymes that are contributing to toxic metabolite accumulation in people who suffer from Stargardt's disease or other lipofuscin disorders. Such enzyme inhibitors include retinoid analogs such as isotretinoin, commonly known by the trademark, ACCUTANE. This drug binds to and inhibits at least two retinal enzymes, known as RPE65 and short chain dehydrogenase, which create surplus metabolites that feed into a pathway that eventually creates toxic metabolites in people with Stargardt's disease. However, isotretinoin treatment alone is not highly effective; therefore, use of zeaxanthin as an adjunctive treatment can improve the efficacy and outcomes of such treatments.

The invention discloses basic nutritional milk shake powder and nutritional milk shake powder for children. The basic nutritional milk shake powder comprises the components by weight percentage as follows: 5-90% of milk powder, 5-90% of maltodextrin, 0.5-35% of cane sugar, 0.1-3% of edible glue, 1-30% of condensed milk powder, 0.018-0.275% of multiple vitamins and 0.746-10.05% of compound mineral substances. The nutritional milk shake powder for children comprises the basic nutritional milk shake powder and further comprises taurine, lactoferrin, DHA (Docosahexaenoic Acid), lutein, zeaxanthin and natural pigments, as well as one or more of fruit and vegetable powder as follows: banana meal, strawberry powder, cranberry powder, mango powder, carrot powder, Hami melon powder, kiwi fruit powder, apple powder, cucumber powder, blueberry powder, mulberry powder and grape powder. The nutritional milk shake powder for children is complete in nutrition, and meanwhile enhances intelligence, eyesight and immunity, and promotes skeletal development.

The invention discloses a method for preparing lycium barbarum lutein by HSCCC (high-speed countercurrent chromatography) separation. The method mainly comprises the following steps: grinding and extracting lycium barbarum berry, concentrating extract, saponifying, eluting and dissolving, and carrying out HSCCC separation to obtain a lycium barbarum lutein solution; concentrating, and freeze-drying to obtain a lutein pure product of which the purity is over 90.6 percent by means of HPLC analysis and detection. According to the method, a methanol and tetrahydrofuran composite solvent is adopted for ultrasonic extraction, and a saponification technology is combined and synergized with HSCCC, so that the problem that main carotinoid lutein and zeaxanthine in lycium barbarum belong to isomers and are difficult to separate can be successfully solved; autumn berry of lycium barbarum is utilized as a raw material, so that the production cost is greatly reduced, effective separation of lutein and zeaxanthine can be successfully realized by repeatedly regulating the solvent proportion in the counter-current chromatography separating and purifying phase, a high-purity lutein monomer can be obtained, and a new thought is provided to implementation of separating and purifying lutein from lycium barbarum and implementation of industrial production.

Zeaxanthin, a dietary carotenoid that occurs in very small quantities in corn, spinach, and other dietary sources, can reduce light hyper-sensitivity and various related conditions (such as migraine or other recurrent headaches) in people who suffer from it. Preferred dosages range from about 10 to about 100 mg per day, depending on the severity of condition, and the weight and medical status of the person. High dosages during an initial “buildup” dosing regimen can promote increased concentrations in the macula and lens, and lower dosages can then be used for maintenance purposes. Lutein may be able to achieve similar results, but because of certain molecular and cellular factors, zeaxanthin is preferable. Additional active agents (such as bilberry or other plant extracts, Vitamins C or E, zinc, etc.) can also be included or coadministered with any such formulations.

The present invention discloses a chewable tablet containing lutein ester, zeaxanthin, blueberries and Chinese wolfberry fruits and a preparation method thereof. The chewable tablet comprises the following components in parts by weight: 1-2 parts of lutein ester, 0.1-0.5 part of zeaxanthin, 10-20 parts of blueberry juice powder, 25-35 parts of Chinese wolfberry fruit juice powder, 5-10 parts of sour and sweet orange powder, 5-10 parts of sweet cherry powder, 20-30 parts of flavoring agents and 0.2-0.6 part of lubricant. The chewable tablets has health-care effects in relieving visual fatigue and improving eyesight, solves problems that the existing products are single in composition and effectiveness, etc., and is good in mouthfeel, convenient to eat, good in absorption effect and more attractive to consumers.

The invention discloses cerasus humilis enzyme and a cerasus humilis enzyme beverage with calcium-supplement eyesight-improving function and a production method thereof. The cerasus humilis enzyme comprises the following raw materials: 1-10 parts of cerasus humilis, 0-5 parts of Chinese wolfberry, 0-1 part of xanthophyll, 0-1 part of taurine, 1-10 parts of honey, 1-10 parts of fructose syrup, 0-1 part of stevioside and 0-3 parts of oligosaccharide, the cerasus humilis enzyme is cleaned, beaten, enzymolyzed, sterilized and fermented into cerasus humilis enzyme raw solution, and the cerasus humilis enzyme raw solution is mixed into the cerasus humilis enzyme beverage. The cerasus humilis enzyme and the cerasus humilis enzyme beverage are rich in special components such as calcium, polyphenols, flavone, zeaxanthin, beta-carotene, polysaccharide and the like, and have a positive effect to soften blood vessel, improve microcirculation, enhance body anti-oxidation ability, delay aging and alleviate visual fatigue.